On the public citation graph
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
0 signed · 94 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamainternmed.2016.6008openalex-snapshot
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
inferredcites →https://doi.org/10.1002/ajh.23544openalex-snapshot
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
inferredcites →https://doi.org/10.1007/s10565-019-09491-7openalex-snapshot
Genome-wide off-targets of drugs: risks and opportunities
inferredcites →https://doi.org/10.1016/j.cell.2017.11.009openalex-snapshot
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
inferredcites →https://doi.org/10.1016/j.csbj.2015.09.001openalex-snapshot
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
inferredcites →https://doi.org/10.1016/j.csbj.2017.07.003openalex-snapshot
Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
inferredcites →https://doi.org/10.1038/leu.2017.252openalex-snapshot
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
inferredcites →https://doi.org/10.1038/nrclinonc.2016.96openalex-snapshot
Combine and conquer: challenges for targeted therapy combinations in early phase trials
inferredcites →https://doi.org/10.1038/srep05193openalex-snapshot
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
inferredcites →https://doi.org/10.1056/nejmoa1900574openalex-snapshot
Ibrutinib and Venetoclax for First-Line Treatment of CLL
inferredcites →https://doi.org/10.1080/14656566.2017.1391216openalex-snapshot
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
inferredcites →https://doi.org/10.1093/bioinformatics/btw230openalex-snapshot
Combenefit: an interactive platform for the analysis and visualization of drug combinations
inferredcites →https://doi.org/10.1093/bioinformatics/btx162openalex-snapshot
SynergyFinder: a web application for analyzing drug combination dose–response matrix data
inferredcites →https://doi.org/10.1093/infdis/jiy304openalex-snapshot
Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures
inferredcites →https://doi.org/10.1093/toxsci/kft223openalex-snapshot
A Correlation Between the In Vitro Drug Toxicity of Drugs to Cell Lines That Express Human P450s and Their Propensity to Cause Liver Injury in Humans
inferredcites →https://doi.org/10.1111/j.1744-7348.1939.tb06990.xopenalex-snapshot
THE TOXICITY OF POISONS APPLIED JOINTLY1
inferredcites →https://doi.org/10.1126/scitranslmed.aaa5597openalex-snapshot
A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity
inferredcites →https://doi.org/10.1128/aac.00474-11openalex-snapshot
Synergistic Drug Combinations for Tuberculosis Therapy Identified by a Novel High-Throughput Screen
inferredcites →https://doi.org/10.1158/0008-5472.can-17-3644openalex-snapshot
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
inferredcites →https://doi.org/10.1182/blood-2016-09-736892openalex-snapshot
Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma
inferredcites →https://doi.org/10.1186/s12943-016-0517-3openalex-snapshot
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.7544openalex-snapshot
Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).
inferredcites →https://doi.org/10.18632/oncotarget.10535openalex-snapshot
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
inferredcites →https://doi.org/10.3109/15563650.2010.495348openalex-snapshot
Colchicine poisoning: the dark side of an ancient drug
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4854716openalex-extracted
Ovicidal Activity of Blending Diaryl Dichalcogenides and Ivermectin Against Fasciola Hepatica: An Alternative for Repurposing the Macrocyclic Lactones Group
inferred← citeshttps://doi.org/10.1002/9781119627784.ch14openalex-snapshot
Combination Therapy Case Studies in Anticancer and Anti‐Infectious Disease Drug Discovery and Development
inferred← citeshttps://doi.org/10.1002/hem3.70282openalex-snapshot
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy
inferred← citeshttps://doi.org/10.1002/ptr.7948openalex-snapshot
Escin enhanced the efficacy of sorafenib by autophagy‐mediated apoptosis in lung cancer cells
inferred← citeshttps://doi.org/10.1002/tox.23988openalex-snapshot
Escin‐sorafenib synergy up‐regulates LC3‐II and p62 to induce apoptosis in hepatocellular carcinoma cells
inferred← citeshttps://doi.org/10.1007/978-1-0716-2095-3_14openalex-snapshot
Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells
inferred← citeshttps://doi.org/10.1007/s11030-023-10784-7openalex-snapshot
Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer
inferred← citeshttps://doi.org/10.1007/s11831-021-09617-3openalex-snapshot
A Comprehensive Review on Deep Synergistic Drug Prediction Techniques for Cancer
inferred← citeshttps://doi.org/10.1007/s11912-023-01485-3openalex-snapshot
Prolymphocytic Leukaemia: an Update on Biology and Treatment
inferred← citeshttps://doi.org/10.1007/s43032-025-01941-4openalex-snapshot
Preventing Preterm Birth: The Search for Tocolytic Synergism
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2024.05.002openalex-snapshot
Exploring cutting-edge strategies for drug repurposing in female cancers – An insight into the tools of the trade
inferred← citeshttps://doi.org/10.1016/j.actatropica.2024.107363openalex-snapshot
Ovicidal activity of diaryl dichalcogenides and ivermectin on Fasciola hepatica: A novel candidate for a blending-based therapeutic strategy
inferred← citeshttps://doi.org/10.1016/j.antiviral.2020.104908openalex-snapshot
Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease
inferred← citeshttps://doi.org/10.1016/j.antiviral.2025.106186openalex-snapshot
Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo
inferred← citeshttps://doi.org/10.1016/j.chembiol.2021.01.026openalex-snapshot
Re-defining synthetic lethality by phenotypic profiling for precision oncology
inferred← citeshttps://doi.org/10.1016/j.drudis.2021.07.023openalex-snapshot
The optimization of combinatorial drug therapies: Strategies and laboratorial platforms
inferred← citeshttps://doi.org/10.1016/j.ijpara.2022.12.003openalex-snapshot
Copper chloride and copper sulphate in combination with nitroxynil against gastrointestinal nematodes of ruminants: A possible hitchhiking synergic effect at low concentrations
inferred← citeshttps://doi.org/10.1016/j.imu.2021.100534openalex-snapshot
Prospect for application of mathematical models in combination cancer treatments
inferred← citeshttps://doi.org/10.1016/j.joi.2024.101617openalex-snapshot
Linkages among science, technology, and industry on the basis of main path analysis
inferred← citeshttps://doi.org/10.1016/j.mib.2021.09.006openalex-snapshot
Leveraging laboratory and clinical studies to design effective antibiotic combination therapy
inferred← citeshttps://doi.org/10.1016/j.phrs.2021.105996openalex-snapshot
iTReX: Interactive exploration of mono- and combination therapy dose response profiling data
inferred← citeshttps://doi.org/10.1016/j.rvsc.2025.105980openalex-snapshot
Repurposing Ebselen for a potential blending-based therapeutic strategy against gastrointestinal nematodes of small ruminants
inferred← citeshttps://doi.org/10.1016/j.tips.2020.01.011openalex-snapshot
Charting the Fragmented Landscape of Drug Synergy
inferred← citeshttps://doi.org/10.1016/j.tiv.2023.105666openalex-snapshot
Gossypol synergises antiproliferative effect of sorafenib in metastatic lung cancer cells following Chou-Talalay algorithm
inferred← citeshttps://doi.org/10.1016/j.vetpar.2020.109317openalex-snapshot
Mentha villosa Hubs., M. x piperita and their bioactives against gastrointestinal nematodes of ruminants and the potential as drug enhancers
inferred← citeshttps://doi.org/10.1016/j.vetpar.2025.110529openalex-snapshot
A blending-based therapeutic strategy using diaryl dichalcogenides and ivermectin against gastrointestinal nematodes of small ruminants
inferred← citeshttps://doi.org/10.1016/j.xcrm.2024.101687openalex-snapshot
A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c00420openalex-snapshot
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.3c00177openalex-snapshot
Space Station-like Composite Nanoparticles for Co-Delivery of Multiple Natural Compounds from Chinese Medicine and Hydrogen in Combating Sensorineural Hearing Loss
inferred← citeshttps://doi.org/10.1038/s41375-023-02122-5openalex-snapshot
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile
inferred← citeshttps://doi.org/10.1038/s41375-025-02577-8openalex-snapshot
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia
inferred← citeshttps://doi.org/10.1038/s41389-024-00510-9openalex-snapshot
Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling
inferred← citeshttps://doi.org/10.1038/s41467-023-44108-yopenalex-snapshot
Mapping combinatorial drug effects to DNA damage response kinase inhibitors
inferred← citeshttps://doi.org/10.1038/s41467-025-66223-8openalex-snapshot
An open-source screening platform accelerates discovery of drug combinations
inferred← citeshttps://doi.org/10.1038/s41575-023-00796-xopenalex-snapshot
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
inferred← citeshttps://doi.org/10.1038/s44386-025-00034-1openalex-snapshot
A review of deep learning approaches for drug synergy prediction in cancer
inferred← citeshttps://doi.org/10.1039/d0dt01882aopenalex-snapshot
Recent advances in MOF-based nanoplatforms generating reactive species for chemodynamic therapy
inferred← citeshttps://doi.org/10.1080/07391102.2022.2091658openalex-snapshot
A new approach used in docking study for predicting the combination drug efficacy in EML4-ALK target of NSCLC
inferred← citeshttps://doi.org/10.1080/17460441.2022.1991306openalex-snapshot
High-throughput screening for drug discovery targeting the cancer cell-microenvironment interactions in hematological cancers
inferred← citeshttps://doi.org/10.1093/bib/bbab293openalex-snapshot
Machine learning approaches for drug combination therapies
inferred← citeshttps://doi.org/10.1093/bib/bbac309openalex-snapshot
Computational models, databases and tools for antibiotic combinations
inferred← citeshttps://doi.org/10.1093/bioinformatics/btag007openalex-snapshot
Characterizing clinical toxicity in cancer combination therapies
inferred← citeshttps://doi.org/10.1093/nar/gkaa216openalex-snapshot
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
inferred← citeshttps://doi.org/10.1093/nar/gkac382openalex-snapshot
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
inferred← citeshttps://doi.org/10.1101/2020.04.25.061333openalex-snapshot
Repurposing Pyramax® for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate
inferred← citeshttps://doi.org/10.1101/2025.10.06.680642openalex-snapshot
ComplexMatrixComb: Predicting Drug Combination IC 50 Doses via Complex Numbers and Matrix Factorization
inferred← citeshttps://doi.org/10.1109/jbhi.2021.3126339openalex-snapshot
Trustworthy Deep Neural Network for Inferring Anticancer Synergistic Combinations
inferred← citeshttps://doi.org/10.1109/tcbbio.2025.3592471openalex-snapshot
Knowledge-Aware Synergistic Discovery of Drug Combinations: A Large Language Model Perspective
inferred← citeshttps://doi.org/10.1126/sciadv.abe4038openalex-snapshot
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
inferred← citeshttps://doi.org/10.1128/mbio.03347-21openalex-snapshot
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
inferred← citeshttps://doi.org/10.1128/spectrum.03331-22openalex-snapshot
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
inferred← citeshttps://doi.org/10.1158/0008-5472.24924158openalex-snapshot
Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
inferred← citeshttps://doi.org/10.1158/0008-5472.24924158.v1openalex-snapshot
Supplementary Data from Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-21-0212openalex-snapshot
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
inferred← citeshttps://doi.org/10.1182/blood.2021011094openalex-snapshot
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
inferred← citeshttps://doi.org/10.1182/blood.2023022884openalex-snapshot
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
inferred← citeshttps://doi.org/10.1186/s12920-025-02130-7openalex-snapshot
Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients
inferred← citeshttps://doi.org/10.1186/s12985-026-03202-5openalex-snapshot
Standardizing antiviral response metrics for mono- and combination therapies in acute, chronic and latent viral infections
inferred← citeshttps://doi.org/10.1186/s13046-024-03173-xopenalex-snapshot
Challenges in validation of combination treatment strategies for CRC using patient-derived organoids
inferred← citeshttps://doi.org/10.1186/s13321-026-01261-yopenalex-snapshot
ComplexMatrixComb: predicting anticancer drug combination dosages for target growth inhibition via complex-number matrix factorization
inferred← citeshttps://doi.org/10.1371/journal.pone.0348908openalex-snapshot
DeepDRP: Dose-response predictions of drug pairs using deep learning based on data-driven feature representation and dose-response curve characteristics
inferred← citeshttps://doi.org/10.1590/s1984-29612026017openalex-snapshot
Efficacy of selenium- and tellurium-based organocompounds against ruminant gastrointestinal nematodes in vitro
inferred← citeshttps://doi.org/10.2174/0113892029281602240422052210openalex-snapshot
Bioinformatics Approaches in the Development of Antifungal Therapeutics and Vaccines
inferred← citeshttps://doi.org/10.2174/0929867328666210504114351openalex-snapshot
Machine Learning in Discovery of New Antivirals and Optimization of Viral Infections Therapy
inferred← citeshttps://doi.org/10.3389/fdsfr.2022.1001614openalex-snapshot
New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research
inferred← citeshttps://doi.org/10.3389/fonc.2022.1075559openalex-snapshot
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
inferred← citeshttps://doi.org/10.3389/fphar.2023.1085765openalex-snapshot
A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis
inferred← citeshttps://doi.org/10.3390/ph15111321openalex-snapshot
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.